Nicholson Garry A
SEC-identified person · CIK 1640861 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Tscan Therapeutics, Inc. TCRX | Director | filed 2024 - 2026 |
| Day One Biopharmaceuticals, Inc. DAWN | Director | filed 2022 - 2026 |
| G1 Therapeutics, Inc. GTHX | Director | filed 2018 - 2024 |
| Nextcure, Inc. NXTC | Director | filed 2020 - 2023 |
| Turning Point Therapeutics, Inc. TPTX | Director | filed 2020 - 2022 |
| Five Prime Therapeutics, INC. FPRX | Director | filed 2017 - 2021 |
| Tesaro, Inc. TSRO | Director | filed 2015 - 2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.